How Retatrutide Works?

What is Retatrutide?

Retatrutide, a new medication created by the pharmaceutical company Eli Lilly, has a major potential for treating obesity and diabetes. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy. When combined with proper diet, regular exercise, and lifestyle modifications, retatrutide can help improve weight loss outcomes and treat comorbidities related to obesity such as diabetes or hypertension (high blood pressure).

How Retatrutide Works?

• Gastric inhibitory polypeptide receptor (GIPR) agonist: As a GIP receptor agonist, retatrutide enhances appetite suppression and prevents fat accumulation, resulting in decreased energy intake and increased energy expenditure.
• Glucagon-like peptide 1 receptor (GLP-1R) agonist: Retatrutide reduces body weight by improving blood sugar levels via enhanced insulin release from the pancreas and reduced release of glucagon (a hormone that increases blood sugar).
• Glucagon receptor (GR) agonist: Retatrutide decreases glucagon release to improve blood sugar levels, decrease food intake, and increase energy expenditure which ultimately results in weight loss.

• Retatrutide Dosage

  Retatrutide is a new drug for obesity that is currently being developed by Eli Lilly. The initial dose of retatrutide is 0.5 mg, which is injected subcutaneously once weekly. The dose of the drug can be increased to 1 mg, 2 mg, or 4 mg after 4 weeks, depending on the patient’s response. The maximum dose is 12 mg per week.

  The initial dose of retatrutide is important because it helps to minimize the risk of side effects. If the patient tolerates the initial dose well, the dose can be increased gradually. However, if the patient experiences any serious side effects, the dose of the drug should be reduced or discontinued. 
• How to buy Retatrutide online?